Cited by 1,506Atrial Fibrillation Management and OutcomesCardiac Valve Diseases and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Eikelboom, John W., Connolly, Stuart J., Brueckmann, Martina, Granger, Christopher B., Kappetein, Arie P., Mack, Michael J., Blatchford, Jon, Devenny, Kevin, Friedman, Jeffrey, Guiver, Kelly, Harper, Ruth, Khder, Yasser, Lobmeyer, Maximilian T., Maas, Hugo, Voigt, Jens-Uwe, Simoons, Maarten L., Van de Werf, Frans·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1300615

Open this paper in CoChat — free account

Abstract

BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level of dabigatran. RESULTS: The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group. In the as-treated analysis, dose adjustment or discontinuation of dabigatran was required in 52 of 162 patients (32%). Ischemic or unspecified stroke occurred in 9 patients (5%) in the dabigatran group and in no patients in the warfarin group; major bleeding occurred in 7 patients (4%) and 2 patients (2%), respectively. All patients with major bleeding had pericardial bleeding. CONCLUSIONS: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1300615

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Oral Anticoagulant Therapy
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
Leon, M. B., Piazza, N., Nikolsky, E., Blackstone, E. H., Cutlip, D. E., Kappetein, A. P., Krucoff, M. W., Mack, M. J., Mehran, R., Miller, D. C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq406 · Cited by 1,217
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124

Flagged first, then by citations

Show all 27 references

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Dewanjee MK, 1999, J Heart Valve Dis, 8, 324

Sorted by citations

Items 501–600 of 1,000

Evaluation of a Pharmacist-Led Remote Warfarin Management Model Using a Smartphone Application (Yixing) in Improving Patients’ Knowledge and Outcomes of Anticoagulation Therapy
Jiang, S., He, Q., Yan, J., Zhao, L., Zheng, Y., Chen, P., & Chen, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.677943 · Cited by 15
“Although new anticoagulants such as rivaroxaban and dabigatran have been shown with increasing utility, the vitamin K antagonist warfarin remains the mainstream in treating thromboembolic diseases, especially for the patients undergoing mechanical heart valve replacement (Eikelboom et al., 2013).”
Background
Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR
Tsai, H. O. N., Goh, J. J. N., Aw, J. W. X., Lin, Y., Fong, A. Y. Y., Tiong, L. L., & Tan, D. S. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1726-y · Cited by 15
The Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi: A Meta-Analysis and Systematic Review
Al-Abcha, A. K., Herzallah, K., Saleh, Y., Mujer, M. T. P., Abdelkarim, O., Abdelnabi, M. H., Almaghraby, A. M., & Abela, G. S. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00458-2 · Cited by 14
Antithrombotic Therapy in the Prevention of Stroke
Bir, S. C., & Kelley, R. E. (2021) · Biomedicines · doi:10.3390/biomedicines9121906 · Cited by 16
Management Challenges in Patients Younger Than 65 Years With Severe Aortic Valve Disease
Baman, J. R., Medhekar, A. N., Malaisrie, S. C., McCarthy, P. M., Davidson, C. J., & Bonow, R. O. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4770 · Cited by 14
Stroke in Atrial Fibrillation and Other Atrial Dysrhythmias
Ozdemir, H., Sagris, D., Lip, G. Y. H., & Abdul‐Rahim, A. H. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01862-1 · Cited by 16
Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation
Ma, C., Wu, S., Liu, S., & Han, Y. (2024) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2024.03.009 · Cited by 16
Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory
Blann, A. D. (2014) · British Journal of Biomedical Science · doi:10.1080/09674845.2014.11669981 · Cited by 14
Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation
Santarpia, G., Curcio, A., Sibilio, G., & Indolfi, C. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0319 · Cited by 15
Approach to the new oral anticoagulants in family practice: Part 1: comparing the options
Douketis, J. D., Bell, A., Eikelboom, J. W., & Liew, A. (2014) · Europe PMC (PubMed Central) · doi:10.25405/ncl.34238934 · Cited by 14
Direct oral anticoagulants: efficacy and safety in patient subgroups
Mavrakanas, T. A., Samer, C. F., Fontana, P., & Perrier, A. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14081 · Cited by 14
Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease
Ahmad, S., & Wilt, H. (2016) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401610010110 · Cited by 14
Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of ‘valvular’ atrial fibrillation: results of the European Heart Rhythm Association Survey
Potpara, T., Lip, G. Y. H., Larsen, T. B., Hernández‐Madrid, A., Dobreanu, D., Jędrzejczyk‐Patej, E., & Dagres, N. (2016) · EP Europace · doi:10.1093/europace/euw302 · Cited by 14
“pared with warfarin in patients with prosthetic mechanical heart valves.(10) However, more data are needed to inform clinical”
Background
Anticoagulation for Thromboembolic Risk Reduction in Adults With Congenital Heart Disease.
Wan, D., Tsui, C., Kiess, M., Grewal, J., Krahn, A., & Chakrabarti, S. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.009 · Cited by 13
Antithrombotic Management of Ischemic Stroke
Sloane, K. L., & Camargo, E. C. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0778-4 · Cited by 13
Thromboembolic risk stratification in atrial fibrillation—beyond clinical risk scores
Wan, D., Andrade, J. G., & Laksman, Z. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202042 · Cited by 15
Dabigatran-Associated Intracranial Hemorrhage
King, A. E., Szarlej, D., & Rincón, F. (2015) · The Neurohospitalist · doi:10.1177/1941874415569069 · Cited by 14
Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of these guidelines as an educational tool for neurologists. Endorsed by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Preventive Cardiovascular Nurses Association
Meschia, J. F., Bushnell, C., Boden-Albala, B. M., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Fornage, M., Goldstein, L. B., et al. (2014) · Cited by 15
Mechanical versus biological aortic valve replacement strategies
Reineke, D., Gisler, F., Englberger, L., & Carrel, T. P. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1133293 · Cited by 14
Apixaban to prevent stroke in patients with atrial fibrillation: a review
Peterson, B. E., Al‐Khatib, S. M., & Granger, C. B. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716652787 · Cited by 14
Characteristics of surgical prosthetic heart valves and problems around labelling: a document from the European Association for Cardio-Thoracic Surgery (EACTS)—The Society of Thoracic Surgeons (STS)—American Association for Thoracic Surgery (AATS) Valve Labelling Task Force
Durko, A. P., Head, S. J., Pîbarot, P., Atluri, P., Bapat, V., Cameron, D. E., Casselman, F. P. A., Chen, E. P., Dahle, G., Ebels, T., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz034 · Cited by 14
In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study
van Zyl, M., Wysokiński, W. E., Jaeger, T. M., Casanegra, A. I., Gersh, B. J., & McBane, R. D. (2020) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.05.003 · Cited by 14
“Nonetheless, average TTR remains well below 70% even in the strict confines of randomized controlled trials (RCTs).(7-12) Monitoring has become more convenient and accessible with the advent of point-ofcare testing and patient self-testing (PST) at home.”
Background
Anticoagulation for Stroke Prevention in Patients with Atrial Fibrillation: A Review of the Literature and Current Guidelines
Vyas, V., Vyas, V., Sharma, A., & Kumar, P. A. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39233 · Cited by 15
Anticoagulation in patients with mechanical heart valves: follow the guidelines!
Verheugt, F. W. A. (2015) · Netherlands Heart Journal · doi:10.1007/s12471-014-0642-9 · Cited by 13
Hemopericardium under dabigatran for stroke prevention in atrial fibrillation
Stöllberger, C., Heger, M., & Finsterer, J. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000553 · Cited by 13
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation
Hernandez, I., Zhang, Y., & Saba, S. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.03.012 · Cited by 13
Anticoagulation Management in Patients with Valve Replacement.
Saksena, D. S., Muralidharan, S., Mishra, Y. K., Kanhere, V. M., Mohanty, B. B., Srivastava, C. P., Mange, J., Puranik, M., Nair, M. P., Goel, P., et al. (2018) · PubMed · Cited by 13
Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements
Zhou, L., Ding, Y., Gao, Y., Yang, B., Bao, J., & Ma, J. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1711883 · Cited by 13
Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical heart valves: a tertiary hospital-based study in Botswana
Botsile, E., & Mwita, J. C. (2020) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2020-006 · Cited by 13
Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
Li, X., Zhang, X., Jin, Q., Xue, Y., Lu, W., Ge, J., Zhou, D., & Lv, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.614762 · Cited by 13
“Recently, clinical trials have prompted a warning against advising anticoagulation with dabigatran in patients with mechanical heart valve replacement mainly due to the enhancement of thrombin receptor expression on platelets and consecutively increased platelet reactivity (Eikelboom et al., 2013).”
Background
Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery
Schulman, S., Cybulsky, I. J., & Delaney, J. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.015 · Cited by 13
“In a recent study with the oral thrombin inhibitor dabigatran after mechanical valve replacement the drug was started from the third postoperative day, reaching full anticoagulant effect within 2 h [16].”
Background
La anticoagulación oral en el anciano con fibrilación auricular no valvular
Fernández, F. V., Jiménez, M. D. R. M., Cerviño, S. M. B., & Losada, M. D. M. M. (2015) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2015.01.005 · Cited by 13
Potential new uses of non–vitamin K antagonist oral anticoagulants to treat and prevent stroke
Yaghi, S. R., Kamel, H., & Elkind, M. S. V. (2015) · Neurology · doi:10.1212/wnl.0000000000001817 · Cited by 13
Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis
Li, Y., Lin, J., & Chen, P. (2016) · Medicine · doi:10.1097/md.0000000000005577 · Cited by 13
Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
Lam, D. H., Bell, S. M., & Hira, R. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0703-4 · Cited by 13
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke
Monteiro, J. M. C., San-Martin, D. L., Silva, B. C. G., de Jesus, P. A. P., & Filho, J. O. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20170180 · Cited by 13
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
Ghaffarpasand, E., Tehrani, M. D., Marszalek, J., & Chi, G. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1693-3 · Cited by 13
“Unlike mechanical valve thrombosis or pump thrombosis in which warfarin is required to suppress the intense activation of contact pathway, intracardiac thrombus develops in a low-flow, low-shear environment and may be effectively managed with NOACs given their efficacy in patients with AF or VTE [26, 27].”
Background
High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood
Nadtochiy, S. M., Baldzizhar, A., Stefanos, T., Feng, C., O’Leary, K. E., Jones-Smith, K. L., Angona, R. E., & Eaton, M. P. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005089 · Cited by 13
Oral anticoagulants and atrial fibrillation: A South African perspective
Laäs, D. J., & Naidoo, M. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i8.13309 · Cited by 13
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin
Whitlock, R. P., Fordyce, C. B., Midei, M. G., Ellis, D. J., Garcia, D. A., Weitz, J. I., Canafax, D. M., Albrecht, D., & Milner, P. G. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-11-0910 · Cited by 12
EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020)
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 12
Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article
Onundarson, P. T., Pálsson, R., Witt, D. M., & Guðmundsdóttir, B. R. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00327-1 · Cited by 15
Oral Anticoagulant Management in Sub-Saharian African Patients with Mechanical Heart Valves: Observations on Quality of Anticoagulation and Thrombotic Risk
Erba, N., Tosetto, A., Langer, M., Abdallah, S. A., Giovanella, E., Lentini, S., Masini, F., Mocini, A., Portella, G., Salvati, A. C., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.09.018 · Cited by 12
Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement
Moser, N., Omar, M. A., Koshman, S. L., Lin, M., Youngson, E. R. E., Kent, W., & Harten, C. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.03.004 · Cited by 13
Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation
Ment, J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s79065 · Cited by 12
Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation
Mohanty, B. D., Looser, P. M., Gokanapudy, L., Handa, R., Mohanty, S., Choi, S. S., Goldman, M. E., Fuster, V., & Halperin, J. L. (2014) · Vascular Medicine · doi:10.1177/1358863x14532869 · Cited by 12
Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians
Abo‐Salem, E., & Becker, R. C. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1060-y · Cited by 12
Safety and Efficacy of Bridging With Low-Molecular-Weight Heparin During Temporary Interruptions of Warfarin: A Register-Based Cohort Study
Sjögren, V., Grzymala-Lubanski, B., Renlund, H., Svensson, P. J., & Själander, A. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617706756 · Cited by 12
Stroke Prevention for High-Risk Atrial Fibrillation in the Emergency Setting: The Emergency Physician Perspective
Atzema, C. L. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.11.009 · Cited by 12
Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring
Poli, S., Härtig, F., Spencer, C., Ebner, M., Birschmann, I., Kühn, J., Faix, S., Ziemann, U., Häring, H., Lehmann, R., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-04-0280 · Cited by 12
Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review
Pallazola, V. A., Kapoor, R. K., Kapoor, K., McEvoy, J. W., Blumenthal, R. S., & Gluckman, T. J. (2019) · Vascular Medicine · doi:10.1177/1358863x18819816 · Cited by 14
Characteristics of Surgical Prosthetic Heart Valves and Problems Around Labelling: A Document From the European Association for Cardio-Thoracic Surgery (EACTS)–The Society of Thoracic Surgeons (STS)–American Association for Thoracic Surgery (AATS) Valve Labelling Task Force
Durko, A. P., Head, S. J., Pîbarot, P., Atluri, P., Bapat, V., Cameron, D. E., Casselman, F. P. A., Chen, E. P., Dahle, G., Ebels, T., et al. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.03.020 · Cited by 12
Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service
Prochaska, J. H., Hausner, C., Nagler, M., Göbel, S., Eggebrecht, L., Panova‐Noeva, M., Arnold, N., Lauterbach, M., Bickel, C., Michal, M., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692175 · Cited by 12
Guidelines for mono, double and triple antithrombotic therapy
van Uden, R. C. A. E., Houtenbos, I., Griffioen‐Keijzer, A., Odekerken, D. A. M., van den Bemt, P. M. L. A., & Becker, M. L. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138938 · Cited by 13
Ex Vivo Assessment of Different Oral Anticoagulant Regimens on Pump Thrombosis in a HeartWare Ventricular Assist Device
RAO, S. D., CONNOR, D. E., Shehab, S., Kerr, N. P., Joseph, J. E., Muthiah, K., Jain, P., Robson, D., Jansz, P. C., & Hayward, C. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007231 · Cited by 12
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 12
Diagnosis and Management of Cardioembolic Stroke
Yaghi, S. R. (2023) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001217 · Cited by 13
Antithrombotic therapy after heart valve intervention: review of mechanisms, evidence and current guidance
Cheng, A., Malkin, C. J., & Briffa, N. P. (2023) · Heart · doi:10.1136/heartjnl-2022-321387 · Cited by 12
Non–Vitamin K Antagonist Versus Vitamin K Antagonist Oral Anticoagulant Agents After Transcatheter Aortic Valve Replacement
Alaour, B., Ferrari, E., Heg, D., Tueller, D., Pilgrim, T., Müller, O., Noble, S., Jeger, R. V., Reuthebuch, O. T., Toggweiler, S., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.11.038 · Cited by 12
Which drug should we use for stroke prevention in atrial fibrillation?
Lau, Y. C., & Lip, G. Y. H. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000065 · Cited by 12
New oral anticoagulants—what the cardiothoracic surgeon needs to know
Kaneko, T., Yammine, M. B., & Aranki, S. F. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.05.060 · Cited by 12
Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study
Christensen, T. D., Skjøth, F., Nielsen, P. B., Maegaard, M., Grove, E. L., & Larsen, T. B. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.09.084 · Cited by 12
Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese
Zeng, W., Xu, Q., Li, C., Chen, W., Sun, X., Wang, X., Yang, Y.-Y., Shi, H. M., & Yang, Z.-S. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2098-x · Cited by 11
Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant
Albrecht, D., Ellis, D., Canafax, D. M., Combs, D. L., Druzgala, P. J., Milner, P. G., & Midei, M. G. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0623 · Cited by 12
Systematic review and meta‐analysis of left ventricular endocardial pacing in advanced heart failure: Clinically efficacious but at what cost?
Graham, A. J., Providenica, R., Honarbakhsh, S., Srinivasan, N. T., Sawhney, V., Hunter, R. J., & Lambiase, P. D. (2018) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13275 · Cited by 12
Incidence, risk factors, and outcomes of warfarin‐associated major bleeding in Thai population
Priksri, W., Rattanavipanon, W., Saejear, W., Tanyasaensook, K., Phrommintikul, A., Chulavatnatol, S., & Nathisuwan, S. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4781 · Cited by 12
“In addition, there are other indications where NOACs have not been shown to be able to replace warfarin, most importantly, for stroke prevention in patients with mechanical heart valve replacement (SPMVR).(7) Due to notable rates of rheumatic heart diseases in the developing countries including Thailand, a sizable pro…”
Background
Structural characterization of anti-UV components from Sasa senanensis Rehder extract.
Matsuta, T., Sakagami, H., Sugiura, T., Kitajima, M., Ōizumi, H., & Oizumi, T. (2013) · PubMed · Cited by 12
New warfarin anticoagulation management model after heart valve surgery: rationale and design of a prospective, multicentre, randomised trial to compare an internet-based warfarin anticoagulation management model with the traditional warfarin management model
Zhu, Z., Li, Y., Xu, M., Han, J., Li, Y., Liu, K., Shen, J., Qin, Y., & Zhang, H. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032949 · Cited by 12
Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease
Gottsäter, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.773214 · Cited by 14
“Warfarin can of course still be used as an alternative for prevention of systemic thromboembolic events in patients with AF or other sources of embolism to peripheral arteries (26), however, and is superior to dabigatran in patients with mechanical heart valves (51) and to rivaroxaban in those with antiphospholipid sy…”
Background
Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection
Garber, J. L., Willenborg, K. L., & Rose, A. E. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1223-5 · Cited by 12
Atrial Fibrillation and Aortic Stenosis
Iung, B., & Algalarrondo, V. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.06.028 · Cited by 12
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Apixaban for Anticoagulation After Robotic Mitral Valve Repair
Mazur, P. K., Arghami, A., Macielak, S. A., Nei, S. D., Viehman, J. K., King, K. S., Daly, R. C., Crestanello, J. A., Schaff, H. V., & Dearani, J. A. (2022) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2022.07.045 · Cited by 12
An update on applications and limitations of direct oral anticoagulants
Wei, S., Sawhney, A., Khandait, H. V., Meda, A., Gupta, V., & Jain, R. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00212-5 · Cited by 11
Anticoagulant Therapy in Pregnant Women with Mechanical Heart Valves: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper
Campello, E., Bucciarelli, P., Catalani, F., Erba, N., Squizzato, A., Poli, D., & Scientific Reviewer Committee (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2325-5658 · Cited by 13
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 16
Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician
Lohrmann, G. M., Atwal, D., Augoustides, J. G., Askar, W., Patel, P. A., Ghadimi, K., Makar, G., Gutsche, J. T., Shamoun, F. E., & Ramakrishna, H. (2016) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2016.01.005 · Cited by 11
The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention
McCarthy, C. P., Verma, S., & Bhatt, D. L. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0930 · Cited by 11
The year in cardiology 2017: valvular heart disease
Søndergaard, L., Saraste, A., Christersson, C., & Vahanian, A. S. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx772 · Cited by 11
2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation
Lee, J., Joung, B., Cha, M., Lee, J. H., Lim, W., Kim, T., Shin, S. Y., Uhm, J., Lim, H. E., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.87.e1 · Cited by 11
State of play and future direction with NOACs: An expert consensus
Cohen, A. T., Lip, G. Y. H., Caterina, R. D., Heidbüchel, H., Zamorano, J. L., Agnelli, G., Verheugt, F. W. A., & Camm, A. J. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.04.001 · Cited by 10
“The early terminated RE-ALIGN trial suggested that dabigatran was associated with an increased risk of stroke, myocardial infarction, thrombosis and bleeding compared to warfarin in patients with mechanical heart valves (112).”
Background
Anesthesiologists Guide to the 2019 AHA/ACC/HRS Focused Update for the Management of Patients With Atrial Fibrillation
Dalia, A. A., Kuo, A. S., Vanneman, M. W., Crowley, J., Elhassan, A. O., & Lai, Y. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.08.046 · Cited by 11
Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation
Cho, M. S., Kim, M., Lee, S., Lee, S., Kim, D., Kim, J., Song, J., Nam, G., Kim, S. J., Kang, D., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.03.050 · Cited by 11
Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation
Zoppellaro, G., Granziera, S., Jose, S. P., Denas, G., Bracco, A., Iliceto, S., & Pengo, V. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1024222 · Cited by 11
When patients on target-specific oral anticoagulants need surgery
Anderson, M., Hassell, K. L., Trujillo, T. C., & Wolfe, B. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13168 · Cited by 13
Dabigatran in clinical practice: Contemporary overview of the evidence
Ageno, W., Eikelboom, J. W., & Lip, G. Y. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.078 · Cited by 11
How I use anticoagulation in atrial fibrillation
Steinberg, B. A. (2016) · Blood · doi:10.1182/blood-2016-07-693614 · Cited by 11
Anticoagulation for the Pregnant Patient with a Mechanical Heart Valve, No Perfect Therapy: Review of Guidelines for Anticoagulation in the Pregnant Patient
Richardson, A., Shah, S., Harris, C., Mcculloch, G., & Antoun, P. S. (2017) · Case Reports in Cardiology · doi:10.1155/2017/3090273 · Cited by 7
Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers
Piran, S., Schulman, S., Panju, M., & Pai, M. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1585-y · Cited by 11
Principles and nursing management of anticoagulation
Gee, E. (2018) · Nursing Standard · doi:10.7748/ns.2018.e11060 · Cited by 11
Warfarin induced leukocytoclastic vasculitis: an extraordinary side effect
Elantably, D., Mourad, A. I., Elantably, A., & Effat, M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01924-8 · Cited by 11
Consensus Report on Patient Blood Management in Cardiac Surgery by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Cardiology (TSC), and Society of Cardio-Vascular-Thoracic Anaesthesia and Intensive Care (SCTAIC)
Ertugay, S. (2019) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2019.01902 · Cited by 11
Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis
Liang, H., He, Q., Zhang, Q., Liu, X., Cui, K., Chen, G., & Xiu, J. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01582-2 · Cited by 11
Management of atrial fibrillation after transcatheter aortic valve replacement: Challenges and therapeutic considerations
Ammar, A. S., Elbatran, A. I., Wijesuriya, N., Saberwal, B., & Ahsan, S. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.007 · Cited by 11
A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies
Nourse, J. P., & Danckwardt, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107676 · Cited by 11
Atrial fibrillation and stroke prevention: state of the art—epidemiology and pathophysiology: new risk factors, concepts and controversies
Kodani, E., & Akao, M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa176 · Cited by 13
“In contrast, the effectiveness or safety of NOACs for ‘valvular’ AF including mechanical heart valves or moderate– severe mitral stenosis has never been proven.(43,44)”
Background
Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment
Barriuso, I., Worner, F., & Vilahur, G. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110397 · Cited by 11
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Plitt, A., Ruff, C. T., & Giugliano, R. P. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.002 · Cited by 11
Anticoagulant Medications for the Prevention and Treatment of Thromboembolism
Brien, L. D. (2019) · AACN Advanced Critical Care · doi:10.4037/aacnacc2019867 · Cited by 11
Update of Anticoagulation Use in Cardioembolic Stroke With a Special Reference to Endovascular Treatment
Safouris, A., Psychogios, K., Palaiodimou, L., Orosz, P., Magoufis, G. L., Kargiotis, O., Theodorou, A., Karapanayiotides, T., Spiliοpoulos, S., Nardai, S., et al. (2024) · Journal of Stroke · doi:10.5853/jos.2023.01578 · Cited by 10

Authors: Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F.
Affiliations: Hamilton Health Sciences (CA)
Boehringer Ingelheim (Germany) (DE)
Duke University (US)
Erasmus MC (NL)
Heart Hospital Baylor Plano (US)
Boehringer Ingelheim (United Kingdom) (GB)
Boehringer Ingelheim (United States) (US)
Boehringer Ingelheim (France) (FR)
KU Leuven (BE)
ORCID: Eikelboom, John W.
Connolly, Stuart J.
Brueckmann, Martina
Granger, Christopher B.
Kappetein, Arie P.
Mack, Michael J.
Blatchford, Jon
Guiver, Kelly
Khder, Yasser
Lobmeyer, Maximilian T.
Voigt, Jens-Uwe
Simoons, Maarten L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-09-26
Volume: 369
Issue: 13
Pages: 1206-1214
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1300615
OpenAlex: W2016875529
Cited by: 1,506
References: 27
Citations by year: 2026: 52 · 2025: 84 · 2024: 111 · 2023: 95 · 2022: 102 · 2021: 140 · 2020: 130 · 2019: 113 · 2018: 119 · 2017: 128 · 2016: 116 · 2015: 131 · 2014: 147 · 2013: 36
FWCI: 97.35
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: dabigatran, warfarin, mechanical heart valves, direct thrombin inhibitors, anticoagulation, thromboembolism, bleeding complications, pericardial bleeding, stroke, aortic valve replacement, mitral valve replacement, dose adjustment
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Female, Heart Valve Prosthesis, Hemorrhage, Humans, Male, Middle Aged, Thromboembolism, Warfarin, beta-Alanine, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks